Conversations: Walking into the Unknown with Howard Marks, David Rosenberg, and Aman Kumar
The Insight by Oaktree Capital
00:00
Shifts in Life Sciences Public Equity Market
This chapter discusses the significant shifts in the life sciences public equity market over the past few years, including volatile valuations during the pandemic and the decline in biotech valuations since February 2021. It identifies the reasons behind this weakness and highlights the increase in non-dilutive financing opportunities in the sector.
Transcript
Play full episode
